Visão geral da empresa
A specialty medical device company, Inspira Technologies Oxy B.H.N. Ltd. focuses on the research, development, manufacturing, and marketing of proprietary life support technologies designed to treat acute respiratory failure within the Israeli market. The firm operates within the Healthcare sector and specifically the Medical Devices industry, positioning itself to serve critical needs in respiratory care and emergency medicine. The company currently maintains a market capitalization of $17.74M, generates annual revenue of $289,000, and employs 34 individuals to support its operations. These financial figures indicate that the entity functions as a micro-cap organization with minimal revenue scale relative to its valuation metrics, suggesting a company in an early-stage or niche operational phase where market capitalization significantly exceeds current sales output.
Saúde financeira
Inspira Technologies reports a trailing twelve-month revenue of $289,000, yet it simultaneously posts a net income of $-13,220,000 and an EBITDA of $-13,473,000, revealing a substantial divergence between top-line activity and bottom-line profitability. The significant gap between the modest revenue figure and the massive net loss implies a highly aggressive cost structure or extensive capital expenditure on research and development that has not yet been offset by sales efficiency. The company generates a free cash flow of $-5,668,375, which indicates that current operational cash outflows are exceeding inflows, thereby limiting immediate financial flexibility for expansion without external financing. Analyzing the margin structure, the gross margin stands at 0.7%, the operating margin is -4713.8%, and the profit margin is 0.0%, highlighting that for every dollar of revenue, the company incurs significant operating costs that prevent the realization of profit. On the balance sheet, the firm holds $3.16M in cash against $480,000 in debt, resulting in a debt-to-equity ratio of 20.66, which suggests a leveraged position where equity capital is the primary buffer against liabilities despite the high debt relative to equity. The current ratio of 1.56 indicates that the company possesses 1.56 dollars in current assets for every dollar of current liabilities, providing a moderate level of short-term liquidity to cover immediate obligations. Furthermore, the return on equity is -397.9% and the return on assets is -127.0%, metrics that reveal management has yet to generate positive returns on shareholder investments or asset bases, pointing to substantial dilution of equity value or asset inefficiency.
Avaliação de valorização
The valuation metrics for Inspira Technologies show a trailing P/E ratio of N/A due to the lack of positive earnings, while the forward P/E is listed at -0.58, implying that expected future earnings remain negative in the immediate forecast horizon. The price-to-book ratio is 6.26, indicating that the market prices the company's equity at more than six times its net asset value, which suggests a significant market premium over book value potentially driven by proprietary technology expectations or strategic positioning. Alternative valuation measures include a price-to-sales ratio of 61.37 and an EV/EBITDA of -1.12, which suggest that the stock is priced on revenue multiples rather than earnings multiples, a common characteristic for high-growth or pre-profitability biotech and medtech firms. Regarding price volatility, the 52-week high is $1.65 and the 52-week low is $0.34, meaning the current price sits at a specific point within this range that reflects recent market sentiment regarding its survival prospects and technological milestones. The beta value of 2.33 indicates that the stock is expected to be 133% more volatile than the broader market, exposing investors to amplified price swings relative to general market movements.
Growth & Income
The revenue growth year-over-year is N/A and the earnings growth year-over-year is also N/A, indicating that the company has not yet established a consistent historical growth trajectory or reported comparable earnings periods for calculation. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, which means the firm reinvests all available capital or retains earnings to fund its research and development initiatives rather than distributing income to shareholders. This reinvestment strategy is typical for medical device startups aiming to commercialize proprietary life support technologies like the INSPIRA ART100, prioritizing long-term product development over current shareholder income generation. Overall, the growth and income profile is characterized by zero current profitability, negative cash flow generation, and a complete absence of dividend payments, reflecting a high-risk, high-potential-reward asset class typical of early-stage healthcare innovators.